Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Hong Kong · Delayed Price · Currency is HKD

19.30

+0.25 (1.31%)

Jul 10, 2026, 9:34 AM HKT

-68.10% (1Y)

Market Cap	6.21B
Revenue (ttm)	54.70M +698.0%
Net Income	-439.90M
EPS	-1.52
Shares Out	325.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	933,800
Open	19.15
Previous Close	19.05
Day's Range	19.10 - 19.58
52-Week Range	15.67 - 206.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2026

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Employees 354

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2659

Full Company Profile

Financial Performance

In 2025, HKG:2659's revenue was 49.16 million, an increase of 697.99% compared to the previous year's 6.16 million. Losses were -395.30 million, 8.47% more than in 2024.

Financial numbers in CNY Financial Statements